The Center for Biosimilars® recaps the top news for the week of September 3, 2018.
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 3.
Number 5: A newly published study in pediatric patients with Crohn disease found that infliximab improved clinical outcome measures from week 2 to week 56.
Number 4: New Zealand’s cost control agency has proposed to stop funding Janssen’s epoetin alfa in favor of funding Novartis’ biosimilar.
Number 3: New research shows that patients may be paying more out of pocket for biosimilar infliximab, and that the advent of biosimilar filgrastim has not expanded access.
Number 2: Celltrion is asking the United Kingdom to lower its threshold to provide access to biologic drugs for patients with rheumatoid arthritis.
Number 1: The FDA heard from 27 speakers, from across the spectrum of stakeholders, at its public hearing on the Biosimilar Action Plan.
Finally, last week, our e-newsletter asked whether you think that the FDA should do away with its current guidance on biosimilar suffixes.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.